Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
early-stage
Biotech
Novartis nixes 6 ph. 1 assets, adds 2 new cancer candidates
The Swiss pharma has scrapped four solid tumor assets and two hematology candidates in a shakeup of its early-stage pipeline.
Darren Incorvaia
Feb 4, 2026 12:09pm
Syncona cites 'challenging' market for switching investment plan
Jun 20, 2025 6:00am
With ph. 1 data, Aura has an eye on early-stage bladder cancer
Oct 17, 2024 4:05pm
Curie.Bio fuels up with $380M for biotech founders
Jun 26, 2024 10:45am
Sofinnova bulks out VC shop with a hefty $548M
Oct 19, 2021 6:25am
Rapha Capital Management launches $100M life science VC fund
Apr 16, 2021 8:50am
